Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy
Frontiers in Immunology, ISSN: 1664-3224, Vol: 11, Page: 601497
2020
- 24Citations
- 48Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations24
- Citation Indexes24
- 24
- Captures48
- Readers48
- 48
Review Description
Immunotherapies have been accelerating the development of anti-cancer clinical treatment, but its low objective responses and severe off-target immune-related adverse events (irAEs) limit the range of application. Strategies to remove these obstacles primarily focus on the combination of different therapies and the exploitation of new immunotherapeutic agents. Nanomedicine potentiates the effects of activating immune cells selectively and reversing tumor induced immune deficiency microenvironment through multiple mechanisms. In the last decade, a variety of nano-enabled tumor immunotherapies was under clinical investigation. As time goes by, the advantages of nanomedicine are increasingly prominent. With the continuous development of nanotechnology, nanomedicine will offer more distinctive perspectives in imaging diagnosis and treatment of tumors. In this Review, we wish to provide an overview of tumor immunotherapy and the mechanisms of nanomaterials that aim to enhance the efficacy of tumor immunotherapy under development or in clinic treatment.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85098749243&origin=inward; http://dx.doi.org/10.3389/fimmu.2020.601497; http://www.ncbi.nlm.nih.gov/pubmed/33408716; https://www.frontiersin.org/articles/10.3389/fimmu.2020.601497/full; https://www.frontiersin.org/articles/10.3389/fimmu.2020.601497/supplementary-material/10.3389/fimmu.2020.601497.s001; http://dx.doi.org/10.3389/fimmu.2020.601497.s001; https://dx.doi.org/10.3389/fimmu.2020.601497; https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.601497/full; https://dx.doi.org/10.3389/fimmu.2020.601497.s001
Frontiers Media SA
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know